UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 1225, 2026

INTELLIGENT BIO SOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39825

82-1512711

(State of

Incorporation)

(Commission

File Number)

(IRS employer

identification no.)

135 West, 41st Street, 5th Floor

New York, NY 10036

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (646) 828-8258

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		INBS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 27.0201 ~~Results~~Regulation ofFD ~~Operations and Financial Condition~~Disclosure.

On February 1225, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing ~~financial~~the ~~results~~successful ~~for~~receipt and deployment of the ~~fiscal~~first ~~quarter~~shipment ~~ended~~of ~~December~~Intelligent ~~31,~~Fingerprinting ~~2025~~Drug Screening Readers manufactured under its new strategic manufacturing partnership with Syrma Johari MedTech Ltd. A copy of the ~~Press~~press ~~Release~~release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing disclosure is qualified in its entirety by the full text of the Press Release.

The information contained ~~herein and~~ in ~~the~~Item ~~accompanying~~7.01 ~~exhibits shall not be incorporated by reference into any filing~~ of ~~the~~this ~~Company, whether~~Current ~~made~~Report ~~before~~on orForm ~~after the date hereof~~8-K, ~~regardless~~including ofExhibit ~~any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing~~99. ~~The information in this report~~1, ~~including~~is ~~the~~being ~~exhibit~~furnished ~~hereto,~~and shall not be deemed to be “filed” for ~~purposes~~the ofpurpose ~~Section 18~~ of the Securities Exchange Act of 1934, as amended, or(the ~~otherwise~~“Exchange ~~subject~~Act”), tonor shall ~~the~~it ~~liabilities~~be ofdeemed ~~that~~incorporated ~~section or~~by ~~Sections~~reference 11in ~~and~~any ~~12(a)(2)~~filing ofunder the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

No.		Description
99.1		Press release dated February 1225, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 12, 2026
Date: February 25, 2026
	INTELLIGENT BIO SOLUTIONS INC.
	By:	/s/ Spiro Sakiris
	Name:	Spiro Sakiris
	Title:	Chief Financial Officer

Filing Compare · INTELLIGENT BIO SOLUTIONS INC.